GU Cancers 2021 | CheckMate 274: nivolumab versus placebo in high-risk urothelial cancer

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses results of the CheckMate 274 trial (NCT02632409), which evaluated the use of the immune checkpoint inhibitor nivolumab versus placebo in high-risk urothelial cancer patients. Results demonstrated improved disease-free survival in patients treated with nivolumab following cystectomy. Further analysis of survival outcomes is needed. This interview took place during the 2021 Genitourinary Cancers Symposium.